The Power of Knowing: Accelerating Alzheimer’s Diagnosis with Biomarker Technology
The Power of Knowing: Accelerating Alzheimer’s Diagnosis with Biomarker Technology
Ahead of care webinar series
A new era in Alzheimer’s diagnostics is here. Join Roche Diagnostics, Ashton Harper and Alison Green, Head of Laboratory Sciences at Scottish Brain Sciences, for an exclusive look at how recent advances in blood-based biomarkers are revolutionising diagnosis and patient care.
In this free webinar, you’ll explore:
-
How biomarker technology supports earlier and more accurate diagnosis
-
The impact of these innovations on patients, clinicians, and healthcare systems
-
What’s coming next in the biomarker landscape
Speakers:
Kyle Buckley MSc FIBMS,
Senior Biomedical Scientist in Clinical Chemistry & Toxicology at Manchester Foundation Trust
Dr Alison Green
Head of Laboratory Sciences, Scottish Brain Sciences
Dr Alison Green is a clinical biochemist with over 30 years’ experience of working within the NHS and academia to develop and evaluate diagnostic tests for neurodegenerative diseases. She did her PhD at the National Hospital for Neurology and Neurosurgery in London looking investigating the role of biomarkers in the diagnosis of dementia. After her PhD, Alison ran the international diagnostic service for Creutzfeldt-Jakob disease within the University of Edinburgh. She is currently working at Scottish Brain Sciences where she is collaborating with Roche Diagnostics Ltd to evaluate the performance of newly emerging blood tests for Alzheimer’s disease.
Dr. Ashton Harper, MBBS, BSc (Hons), MRCS
Head of Medical Affairs, Roche Diagnostics UK and Ireland
Ashton has been the Global Medical Affairs Indication Lead for Neurosciences since 2025. In this role, he provides strategic direction for Roche Diagnostics' rapidly growing neurology portfolio, focusing on evidence generation, external collaborations, medical education, and KOL engagement. Ashton joined Roche Diagnostics in August 2020 as the Head of Medical Affairs for the UK & Ireland. He led a team responsible for clinical research across various therapeutic areas, including oncology, cardiology, neurology, infectious diseases, critical care, and women’s health. Before joining Roche, Ashton began his career in the life sciences industry in 2015 as a Medical Advisor at Protexin, a UK-based biotechnology company specializing in microbiome-focused products. He later served as the company’s Medical Director following its acquisition by ADM in 2018.
Outside of his role at Roche, Ashton has been the UK & Ireland Chapter Lead of the Medical Affairs Professional Society since February 2022. This non-profit organization is dedicated to enhancing the value that medical affairs brings to patients, healthcare, and the life sciences industry.
Unable to attend the live event? Please register to receive access to the webinar recording after the session.
Ahead of Care webinar series
Co-hosted by Roche and LabMed this webinar series looks at improving patient care through innovative, sustainable, and connected solutions. Join us to explore what the future could look like.
